Patients’ accounts of increased “Connectedness” and “Acceptance” after psilocybin for treatment-resistant depression

Over the past decade there has been renewed interest in the therapeutic use of classical psychedelics, with modern clinical trials reporting promising safety, tolerability and preliminary efficacy. Watts and colleagues note that much of the recent work has concentrated on conventional symptom-based outcomes, leaving a relative paucity of qualitative investigation into the psychological mechanisms by which psychedelic-assisted treatments might work. The present study was motivated to fill that gap by exploring patients’ own accounts of their experiences following psilocybin treatment for treatment‑resistant depression (TRD), with a view to clarifying candidate psychological processes that might underlie clinical change. This paper reports a thematic, phenomenological analysis of semi‑structured interviews conducted at six months after dosing in the first modern clinical trial of psilocybin for TRD. The core research questions asked what patients experienced during dosing, how they felt in the weeks and months afterwards, what processes of change they identified, and how they compared psilocybin with prior treatments. The study is presented as a qualitative complement to forthcoming formal quantitative and neuroimaging reports from the same trial.

Participants were recruited from a single open‑label clinical trial of psilocybin for TRD conducted at Imperial College London. The trial enrolled 20 patients who met the study definition of TRD (Hamilton Depression Rating Scale score 17+ and failure of at least two antidepressant medications within the current episode). Extracted demographic information indicates six women and 13 men aged 30–64 years, and an ethnic breakdown of 15 White, 3 Black, 1 Asian and 1 Hispanic; the extracted text also states that five participants had prior psychedelic experience and that all but one had tried cognitive behavioural therapy. Key exclusion criteria reported included no personal or first‑degree family history of psychotic disorder. There is a small inconsistency in the extraction about the qualitative sample: one passage states that all 20 took part in the follow‑up, whereas the Procedures section reports that 19 gave informed consent and were interviewed; the extracted text does not clearly resolve this discrepancy. Procedures involved semi‑structured interviews conducted approximately six months after the high‑dose session. Interviews (lasting about an hour) followed a schedule covering pre‑study depression, treatments tried, the dosing experience, post‑treatment changes, and comparisons with prior care; prompts were used to encourage elaboration. Interviews were recorded and transcribed by the first author (Watts), who also acted as a guide for three patients (these cases are marked in the transcripts). Thematic analysis using a constant comparison approach was applied sequentially by the first author. Other study team members read transcripts to verify that identified themes fairly represented the dataset, and respondent validity checks were carried out. Contextual trial procedures relevant to interpretation are also described in the extracted text: in the parent clinical trial each patient had preparatory sessions, a low (10 mg) and a high (25 mg) psilocybin session with supportive ‘‘guides’’ present, and brief integration sessions the day after and one week after the high dose. Dosing sessions took place with eyeshades and a fixed music playlist designed to encourage introspective focus; guides periodically ‘‘checked in’’ and provided reassurance and encouragement to surrender to the experience. The therapeutic stance emphasised humanistic skills (empathy, unconditional positive regard, genuineness). The extracted text also reports preliminary quantitative trial outcomes (large effect sizes in the first five weeks, reduced but still sizable effects at three and six months), though full clinical and neuroimaging reports were noted as forthcoming.

Thematic analysis yielded three overarching themes: (1) depression conceptualised by participants as a state of disconnection (from self, others, senses and the world) that psilocybin appeared to reverse; (2) a shift from avoidance of emotion to acceptance following dosing; and (3) participants’ comparisons between the psilocybin intervention and prior conventional treatments, with the latter often seen as reinforcing disconnection and avoidance. Theme 1 (disconnection to connection): Prior to treatment patients commonly described being ‘‘trapped in the prison of the mind,’’ with intense rumination, diminished sensory responsiveness and a diminished sense of self. Social withdrawal and isolation were prominent; several participants reported reduced capacity for touch, pleasure and engagement with the external world. After psilocybin, many reported sudden, sometimes dramatic, changes in consciousness described with metaphors such as ‘‘rebooted’’ or ‘‘reset’’: increased mental clarity, reduced rumination and an enduring sense of mental spaciousness for weeks to months. Seventeen participants reportedly experienced intense subjective drug effects and gave rich accounts of sensory reconnection during dosing (visual, tactile and music‑evoked phenomena). Improvements in sensory pleasure (for example, renewed enjoyment of music and nature) were reported by multiple participants. Connection to the self emerged as a common outcome: increases in self‑worth, self‑compassion and re‑engagement with past hobbies, work and social roles were frequently described. Social reconnection included strengthened close relationships, easier interactions with strangers, and in some cases expanded concern for humanity and nature. Spiritual‑like or unitive experiences were reported by some participants who had not previously identified as spiritual; religious imagery and feelings of unconditional love were also described. The extract notes that three patients had minimal subjective effects during dosing (two reporting no effects and no clinical benefit), and that those with more pronounced acute experiences tended to provide richer qualitative material and, implicitly, better clinical outcomes. Theme 2 (avoidance to acceptance): Before treatment many participants described constricted emotional repertoires, longstanding avoidance or suppression of difficult emotions and trauma memories, and use of substances or behaviours to numb feelings. During dosing sessions intense and often labile emotions were common (joy, grief, terror, love), with many participants describing cathartic sobbing (10 patients reportedly cried during sessions) and embodied emotional release. Several participants recounted confronting childhood trauma memories during the dose, sometimes in fragmentary, multisensory form, and subsequently reporting new understanding of how these events related to later difficulties. For many, surrendering to painful affect in the session led to lasting openness to emotion, reduced avoidance, improved emotional expression in relationships and behavioural changes (diet, exercise, reduced alcohol use). Two participants who showed less symptomatic improvement after treatment reported difficulty ‘‘letting go’’ during their sessions, suggesting that the capacity to surrender may be a moderator of response. Theme 3 (comparison with prior treatments): Participants were generally critical of prior conventional care. Common critiques were that talking therapies (most often CBT) were brief, directive, difficult to access, and sometimes retraumatising or insufficiently containing, while antidepressants were described as blunting emotions and promoting avoidance of underlying problems. In contrast, the psilocybin treatment was valued for its extended preparation, long dosing sessions (up to several hours), the music‑facilitated journey, skilled guides and integration sessions. Many participants reported durable subjective benefits even when formal depressive symptoms had partly returned. All participants stated they would like to undergo psilocybin treatment again and some expressed interest in booster doses, with a modal suggested interval of about 3 months. A subset (three participants) reportedly sought additional psilocybin elsewhere after relapse; outcomes of these additional doses were mixed. Adverse events of note in the extracted text were limited: no enduring psychoses or persisting perceptual disorder were reported; one participant (P14) experienced initial distress around a putative re‑experienced childhood suffocation memory but adjusted after integration; another (P15) became uncommunicative for 2–3 hours during a highly intense but physiologically stable and subjectively ‘‘blissful’’ peak. Two participants described negative interactions with guides. The extracted clinical outcome summary reported earlier in the document states that 15 of 20 showed some reduction in depressive symptoms at six months, with 7 meeting clinical response criteria (≥50% reduction) and 6 meeting remission by standard criteria, although later narrative passages mention three participants self‑describing as ‘‘depression‑free’’ and an additional four formally in remission, an inconsistency that is not clearly resolved in the extracted text.

Watts and colleagues interpret the qualitative findings as indicating two principal change processes by which psilocybin‑assisted therapy helped patients with treatment‑resistant depression: a shift from disconnection to connection, and a shift from avoidance of painful emotion to acceptance and processing. The authors highlight how participants contrasted psilocybin with prior treatments, characterising antidepressants and many short, directive talking therapies as reinforcing numbing and withdrawal, while psilocybin‑assisted sessions were reported to facilitate emotional access, reconnection to self and others, and renewed meaning and purpose. The researchers situate these reports alongside emerging neurobiological models: psychedelics’ agonism at 5‑HT2A receptors and acute neuroimaging signals of increased brain plasticity are proposed as mechanisms that transiently render the brain more malleable, thereby enabling psychological change when combined with appropriate psychological set and setting. The authors use the analogy of annealing — a temporary increase in malleability that facilitates reorganisation — and propose that drug × environment interactions (including preparatory work, music and skilled guidance) are likely crucial determinants of therapeutic outcome. Several therapeutic frameworks are discussed as potentially complementary to psychedelic treatment. The authors note parallels with depth psychology and Jungian concepts, and suggest that Acceptance and Commitment Therapy (ACT) may align well with the observed processes by fostering psychological flexibility, willingness to experience painful emotions, present‑moment contact and value‑directed action. Group therapy is also suggested as a possible adjunct, given the prominence of reconnection themes. Limitations and uncertainties acknowledged by the authors include selection and expectation biases (self‑selection of participants, positive expectations, and a high level of attention from the research team), potential demand characteristics and the first author’s dual role as interviewer and guide for three participants. They also note that the sample was composed of treatment‑resistant patients who tended to hold negative views of prior treatments, which may have influenced comparative judgments. The authors recommend future research to control for these biases (for example by recruiting via external referral, measuring baseline expectations) and to experimentally vary and standardise psychological and environmental components (including music) to determine which elements are essential for beneficial outcomes. Implications for research and measurement are emphasised: the authors suggest that standard symptom scales may not fully capture meaningful changes reported by participants (for example, increased sense of meaning, engagement and psychological well‑being) and that outcome measures sensitive to positive wellbeing might be useful. They also call for further qualitative work across other indications (addiction, OCD, end‑of‑life anxiety) and for trials that test combinations of psychedelic dosing with evidence‑based psychotherapies, booster dosing strategies and different care models. The extracted text closes by reiterating that the qualitative themes reported here complement quantitative findings and can help generate testable hypotheses about the mechanisms and optimisation of psychedelic‑assisted therapies.